CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy
CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), a propensity score matching analysis published in the journal Cancer has shown.1

Both dasatinib and nilotinib are approved by the US Food and Drug Administration as frontline therapy for CMP-CP based on findings from randomized trials compared with imatinib; however, no head-to-head trial has compared dasatinib with nilotinib in this patient population.

For the study, investigators analyzed data from 102 patients with CML-CP who received dasatinib and 104 who had nilotinib as part of 2 phase 2 trials conducted in parallel. A total of 87 patients from each trial were matched for pretreatment characteristics.

Results showed that the 3-month BCR-ABL1/ABL1 ratio < 10% rate was 93% with dasatinib and 94% with nilotinib (P =.25).

In addition, the rates of major molecular response at 12 months were 77% and 85%, respectively (P =.13), and the rates of molecular response with 4.5-log reduction in the ratio at 36 months were 66% and 64%, respectively (P =.96).

Researchers also found that the 3-year overall survival probabilities were 99% for dasatinib-treated patients and 93% for nilotinib-treated patients (P =.95).

The study further demonstrated a similar treatment discontinuation rate between the 2 groups (P =.82).

The findings ultimately highlight that both nilotinib and dasatinib can be considered valid standard-of-care options for the first-line treatment of patients with CML-CP.

Reference

1. Takahashi K, Kantarjian HM, Yang Y, et al. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Aug 10. doi: 10.1002/cncr.30197. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs